SC
OCUL icon

Scotia Capital’s Ocular Therapeutix OCUL Stock Holding History

Scotia Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Hold
13,337
– – ﹤0.01% 876
2026
Q1 		$113K Buy
+13,337
New +$127K ﹤0.01% 881
2024
Q4 		– Sell
-12,138
Closed -$106K – 901
2024
Q3 		$106K Buy
+12,138
New +$100K ﹤0.01% 803

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Scotia Capital's OCUL Position: Q2 2026 in Review

Scotia Capital held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 13,337 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Scotia Capital first reported a position in OCUL in Q3 2024 and has held it in 3 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Scotia Capital held 13,337 shares of Ocular Therapeutix worth $131K as of Q2 2026.
  • Scotia Capital left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Scotia Capital's portfolio in Q2 2026, its #876 holding.
  • Scotia Capital first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 3 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.